ArticleScientific reports2025
A PBPK modeling approach for personalized dose optimization of nicardipine in renal and hepatic dysfunction.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Development and Evaluation of Physiologically Based Pharmacokinetic (PBPK) Models to Investigate the Effect of CYP2D6 Polymorphism on Metoclopramide Systemic Exposure.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Model-guided dose optimization of cefoperazone-sulbactam and levofloxacin for pneumonia and urinary tract infections in patients with hepatic dysfunction.American journal of translational research · 2026Article
- A Comprehensive Physiologically Based Pharmacokinetic Framework of Ofloxacin: Predicting Disposition in Renal Impairment.Pharmaceutics · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Nicardipine is a calcium channel blocker employed to manage hypertension and angina. It is primarily metabolized in the liver; therefore, hepatic impairment patients may experience drug accumulation, potentially resulting in adverse events. This research aims to design physiologically based pharmacokinetic (PBPK) model capable of accurately predicting the exposure of nicardipine in healthy individuals as well as hepatic and renal impairment patients. An extensive literature review was conducted to retrieve relevant articles and pharmacokinetic (PK) parameters of nicardipine, for integration into the PK-Sim
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.